The technology described herein is directed to compositions comprising CAGE and at least one active compound, e.g., for oral or parenteral administration.

A method of treating cervical intraepithelial neoplasia (CIN) or cervical cancer in a subject is disclosed. The method can include topically administering to an affected area of the subject a composition comprising a plurality of taxane nanoparticles, thereby treating the CIN or the cervical cancer. The taxane nanoparticles can be uncoated (neat) individual particles that are not encapsulated in, bound to, or conjugated to any substance.

A method of treating cervical intraepithelial neoplasia (CIN) or cervical cancer in a subject is disclosed. The method can include topically administering to an affected area of the subject a composition comprising a plurality of taxane nanoparticles, thereby treating the CIN or the cervical cancer. The taxane nanoparticles can be uncoated (neat) individual particles that are not encapsulated in, bound to, or conjugated to any substance.

Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reduction of resistance to the treatment, prevention, and/or diagnosis of diseases characterized by the formation of cancers. Embodiments include methods of treating cancer, comprising the steps of: providing a patient diagnosed with cancer with a therapeutic regime that includes at least one therapeutically effective dose of at least one agent that reduces the activity of at least one DNA damage/repair pathway. Other embodiments include methods of treating cancer, comprising the steps of: treating a patient diagnosed with cancer with a combination of therapeutic agents that includes at least one therapeutically effective anti-cancer agent and at least one compound that reduces the activity of at least one DNA damage/repair pathway. Yet other embodiments include methods of reducing resistance to a genotoxic therapeutic, comprising the steps of: treating a patient at least one therapeutically effective dose of at least one agent that reduces at least one DNA damage/repair pathway.

The technology described herein is directed to compositions comprising CAGE and at least one active compound, e.g., for oral or parenteral administration.

The invention relates to cytotoxic conjugates and antibody-drug conjugates, and to their use in therapy, in particular for treating HER2+ cancers.

The invention relates to cytotoxic conjugates and antibody-drug conjugates, and to their use in therapy, in particular for treating HER2+ cancers.

Disclosed are surprising new methods and kits for treating patients, particularly cancer patients, using bavituximab in combination therapies with immuno-oncology (IO) agents such as checkpoint inhibitor antibodies. The methods and kits are based on the surprising finding that human patients treated with bavituximab and checkpoint inhibitor antibodies have a statistically significant prolonged survival in controlled studies.

Disclosed are surprising new methods and kits for treating patients, particularly cancer patients, using bavituximab in combination therapies with immuno-oncology (IO) agents such as checkpoint inhibitor antibodies. The methods and kits are based on the surprising finding that human patients treated with bavituximab and checkpoint inhibitor antibodies have a statistically significant prolonged survival in controlled studies.

Disclosed are surprising new methods and kits for treating patients, particularly cancer patients, using bavituximab in combination therapies with immuno-oncology (IO) agents such as checkpoint inhibitor antibodies. The methods and kits are based on the surprising finding that human patients treated with bavituximab and checkpoint inhibitor antibodies have a statistically significant prolonged survival in controlled studies.